Urodynamic and Frequency-Volume Chart Parameters Influencing Anticholinergic Resistance in Patients With Neurogenic Detrusor Overactivity
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Neurogenic detrusor overactivity (NDOA) is characterized by involuntary detrusor muscle contractions during bladder filling in patients with neurological disorders. Anticholinergic therapy is the primary treatment; however, the reasons for treatment resistance in NDOA are not well understood. This study aimed to identify predictors of treatment failure by comparing urodynamic and frequency-volume chart data between patients with NDOA who respond and patients who do not respond to anticholinergic therapy. Methods: We reviewed the records of 362 patients presenting with lower urinary tract symptoms and selected 85 who had NDOA and were on anticholinergic therapy. Ultimately, 67 patients were analyzed. We categorized these individuals into responders (group R) and nonresponders (group NR) based on clinical and urodynamic improvements. Three-day frequencyvolume charts and urodynamic study results were retrospectively reviewed. Results: Of the 85 initial patients, 12 refused medication, and 6 were lost to follow-up. Pre- to posttreatment changes differed significantly between groups in the number of urgency urinary incontinence (UUI) episodes per 24 hours (P=0.001), maximum cystometric capacity (mL, P=0.003), NDOA frequency (P=0.004), and bladder compliance (mL/cm H2O, P=0.003). Multivariate analysis revealed that NDOA frequency (P=0.014) and UUI episodes per 24 hours (P=0.002) were significant factors associated with treatment failure. Conclusions: NDOA varies according to underlying neurological conditions. The frequencies of UUI episodes and NDOA in urodynamic studies can predict resistance to initial anticholinergic treatment.
Abstract
Purpose: Neurogenic detrusor overactivity (NDOA) is characterized by involuntary detrusor muscle contractions during bladder filling in patients with neurological disorders. Anticholinergic therapy is the primary treatment; however, the reasons for treatment resistance in NDOA are not well understood. This study aimed to identify predictors of treatment failure by comparing urodynamic and frequency-volume chart data between patients with NDOA who respond and patients who do not respond to anticholinergic therapy. Methods: We reviewed the records of 362 patients presenting with lower urinary tract symptoms and selected 85 who had NDOA and were on anticholinergic therapy. Ultimately, 67 patients were analyzed. We categorized these individuals into responders (group R) and nonresponders (group NR) based on clinical and urodynamic improvements. Three-day frequencyvolume charts and urodynamic study results were retrospectively reviewed. Results: Of the 85 initial patients, 12 refused medication, and 6 were lost to follow-up. Pre- to posttreatment changes differed significantly between groups in the number of urgency urinary incontinence (UUI) episodes per 24 hours (P=0.001), maximum cystometric capacity (mL, P=0.003), NDOA frequency (P=0.004), and bladder compliance (mL/cm H2O, P=0.003). Multivariate analysis revealed that NDOA frequency (P=0.014) and UUI episodes per 24 hours (P=0.002) were significant factors associated with treatment failure. Conclusions: NDOA varies according to underlying neurological conditions. The frequencies of UUI episodes and NDOA in urodynamic studies can predict resistance to initial anticholinergic treatment.
참고문헌 (12)
- Chancellor MB, "Pharmacotherapy for neurogenic detrusor overactivity", Am J Phys Med Rehabil, 85, pp.536~545 (2006)
- Madhuvrata P, "Anticholinergic drugs for adult neurogenic detrusor overactivity : a systematic review and meta-analysis", Eur Urol, 62, pp.816~830 (2012)
- Stöhrer M, "EAU guidelines on neurogenic lower urinary tract dysfunction", Eur Urol, 56, pp.81~88 (2009)
- Benner JS, "Patient-reported reasons for discontinuing overactive bladder medication", BJU Int, 105, pp.1276~1282 (2010)
- Goldman HB, "Defining response and non-response to treatment in patients with overactive bladder : a systematic review", Curr Med Res Open, 30, pp.509~526 (2014)
- Amend B, "Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects", Eur Urol, 53, pp.1021~1028 (2008)
- Manack A, "Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database", Neurourol Urodyn, 30, pp.395~401 (2011)
- Tijnagel MJ, "Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder : a prospective cohort study with solifenacin", BMC Urol, 17, pp.30~ (2017)
- . Regardless of concomitant anticholinergic use or neurologic etiology, "Adv Ther", 2013, 819~833
- Cruz F, "Chapter 5 : clinical data in neurogenic detrusor overactivity(NDO)and overactive bladder(OAB)", Neurourol Urodyn, 33(Suppl 3), pp.S26~S31 (2014)
- Stöhrer M, "Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study", Eur Urol, 51, pp.235~242 (2007)
- Harding C, "Is low bladder compliance predictive of detrusor overactivity?", Neurourol Urodyn, 28, pp.74~77 (2009)